Erythromycin ethylsuccinate-13C, d3

O=C(O[C@H]1[C@H](O[C@@H]([C@](C)(O)C[C@H]2C)[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C2=O)=O)O[C@H](C)C[C@@H]1N(C)[13C]([2H])([2H])[2H])CCC(OCC)=O

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Feng YC, et al. Construction of universal quantitative models for determination of roxithromycin and erythromycin ethylsuccinate in tablets from different manufacturers using near infrared reflectance spectroscopy. J Pharm Biomed Anal. 2006 May 3;41 (2) :373-84.|[3]Gustafsson A, et al. The association of erythromycin ethylsuccinate with acute colitis in horses in Sweden. Equine Vet J. 1997 Jul;29 (4) :314-8.|[4]Komuro I, et al. Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBPbeta. Proc Natl Acad Sci U S A. 2008 Aug 26;105 (34) :12509-14.